Oruka Therapeutics (NASDAQ:ORKA) Stock: Insider Lawrence Otto Klein Sells 25,000 Shares

Oruka Therapeutics, Inc. (NASDAQ:ORKA) CEO Lawrence Klein sold 25,000 shares of the company’s stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $95.60, for a total value of $2,390,000.00. Following the completion of the sale, the chief executive officer owned 923,128 shares in the company, valued at approximately $88,251,036.80. This represents a 2.64% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Lawrence Otto Klein also recently made the following trade(s):

• On Thursday, October 1st, Lawrence Klein sold 25,000 shares of Oruka Therapeutics stock. The stock was sold at an average price of $83.62, for a total transaction of $2,090,500.00.
• On Tuesday, September 15th, Lawrence Klein sold 2,452 shares of Oruka Therapeutics stock. The stock was sold at an average price of $95.71, for a total transaction of $234,680.92.
• On Tuesday, September 1st, Lawrence Klein sold 75,000 shares of Oruka Therapeutics stock. The stock was sold at an average price of $91.83, for a total transaction of $6,887,250.00.

Oruka Therapeutics Trading Down 1.5%

NASDAQ ORKA traded down $1.44 on Monday, hitting $95.43. 654,336 shares of the company’s stock traded hands, compared to its average volume of 1,079,825. The firm’s 50-day moving average price is $88.47 and its two-hundred day moving average price is $68.90. The firm has a market capitalization of $6.32 billion, a PE ratio of -47.01 and a beta of -0.37. Oruka Therapeutics, Inc. has a 1-year low of $25.23 and a 1-year high of $115.51.

Oruka Therapeutics (NASDAQ:ORKA) last issued its earnings results on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.04). On average, research analysts anticipate that Oruka Therapeutics, Inc. will post -2.42 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ORKA has been the subject of a number of analyst reports. Mizuho set a $120.00 price target on Oruka Therapeutics in a report on Thursday, September 3rd. HC Wainwright reaffirmed a “buy” rating on shares of Oruka Therapeutics in a research note on Tuesday, October 27th. BTIG Research reaffirmed a “buy” rating and set a $151.00 target price on shares of Oruka Therapeutics in a report on Monday, October 19th. Guggenheim reaffirmed a “buy” rating and set a $200.00 target price on shares of Oruka Therapeutics in a report on Monday, October 26th. Finally, Piper Sandler reiterated an “overweight” rating on shares of Oruka Therapeutics in a research note on Wednesday, October 7th. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Oruka Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $133.00.

Hedge Funds Weigh In On Oruka Therapeutics

A number of hedge funds have recently bought and sold shares of ORKA. BlackRock Inc. purchased a new stake in shares of Oruka Therapeutics in the second quarter valued at approximately $474,916,000. Jupiter Topco LLC purchased a new stake in Oruka Therapeutics in the 2nd quarter worth $130,968,000. Bank of America Corp DE purchased a new stake in Oruka Therapeutics in the 2nd quarter worth $33,578,000. Braidwell LP acquired a new position in Oruka Therapeutics during the second quarter worth $26,473,000. Finally, Atika Capital Management LLC acquired a new position in Oruka Therapeutics during the first quarter worth $11,277,000. Hedge funds and other institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc (NASDAQ: ORKA) is a clinical-stage biopharmaceutical company developing long-acting antibody therapies for immune-mediated diseases. The company is focused on creating treatments that may provide durable disease control while reducing the frequency of administration compared with conventional biologic therapies.

Oruka’s pipeline is centered on engineered monoclonal antibodies that target the interleukin-17 (IL-17) pathway, an important driver of inflammation in conditions such as psoriasis and other autoimmune diseases.